{"contentid": 488410, "importid": NaN, "name": "Issar Pharma out-licenses peptide-based NCEs", "introduction": "Issar Pharmaceuticals, the only company in India which focuses on research and development of New Chemical Entities (NCE), is licensing out its NCEs based on peptide technology, with pre-IND filing and US Patents, opening opportunities for fruitful partnerships.", "content": "<p>Issar Pharmaceuticals, the only company in India which focuses on research and development of New Chemical Entities (NCE), is licensing out its NCEs based on peptide technology, with pre-IND filing and US Patents, opening opportunities for fruitful partnerships.</p>\n<p>The potential collaboration would help ISSAR in its goal to design and deliver novel peptide-based drugs for various unmet healthcare needs of the population, and making it affordable and accessible for better health outcomes.</p>\n<p>Issar uses solid-phase peptide synthesis as the technology of choice, and has the capability to synthesize custom peptides, API peptides and cosmetic peptides at all scales within a short duration. With emphasis on quality, safety and innovation, Issar has demonstrated the ability to move products from conceptualization to commercialization of peptide molecules at all stages. Issar has several patents for potential life changing peptide molecules lined up in their development pipeline targeting therapeutic areas such as oncology, dermatology, gastroenterology and diseases of bones and joints.</p>\n<p>&ldquo;We take pride in being India&rsquo;s first ever company to conduct Phase I clinical trials, and launch the first ever indigenous peptide drug, Melgain (decapeptide) in market for the treatment of vitiligo in 2004,&rdquo; said Ramakrishna Reddy Isanaka, the founder of Issar.</p>\n<p>Issar&rsquo;s Food and Drug Administration-compliant state-of-the-art manufacturing facility of 62000 sq ft, is purely into peptide manufacturing technology, located in Genome valley, Hyderabad, India. In addition to its experience in R&amp;D, Issar is equipped with the most advanced and automatic technology with expertise in the synthesis and purification of peptides, producing highest standards of purity of up to 99.5% by continued process optimization.</p>\n<p>With over 25 years of experience and prime focus in research and development, Issar&rsquo;s dedicated team of experts are proud to have developed India&rsquo;s first ever peptide molecule, Melgain for the treatment of vitiligo in 2004, which is now introduced as Novoskin with improved properties and effectiveness. ISSAR&rsquo;s commitment has also led to the development of their second New Chemical Entity called Xylentra, which is the first ever peptide drug in the world for the treatment of burn wounds and microbial infections.</p>\n<p>Issar developed molecules for prevalent conditions in the Western world such as inflammatory bowel diseases (IBD), psoriasis and sepsis. Recently, an NCE for the treatment of burn-wounds (Xylentra) was licensed to Viatris (Nasdaq: VTRS), formerly known as Mylan Laboratories, USA in 2020.</p>", "date": "2021-04-21 10:12:00", "meta_title": "Issar Pharma out-licenses peptide-based NCEs", "meta_keywords": "Issar Pharma, NCEs, Peptide-based, Out-licenses, Melgain, Xylentra", "meta_description": "Issar Pharma out-licenses peptide-based NCEs", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-21 09:21:21", "updated": "2021-04-21 10:12:49", "access": NaN, "url": "https://www.thepharmaletter.com/article/issar-pharma-out-licenses-peptide-based-nces", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "indianpharmabig.jpg", "image2id": "indianpharmasmall.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Dermatologicals", "topic_tag": "Deals, Licensing", "geography_tag": "India", "company_tag": "Issar Pharma", "drug_tag": "Melgain, Xylentra", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-21 10:12:00"}